Rollout of efavirenz-based regimens in option B+ in the prevention of mother-to-child transmission programs: challenges and lessons learned from a postexposure prophylaxis experience.
aDepartment of Immunology, Trinity College Dublin, Dublin, Ireland bInfectious Diseases Institute, College of Health Sciences Makerere University, Kampala, Uganda cRwanda Military Hospital, Kigali, Rwanda.
Judy T
JT
Orikiiriza
D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D048588:Benzoxazines / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000635:transmission*; D006212:Hallucinations / Q000139:chemically induced*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D056990:Post-Exposure Prophylaxis; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz